Preventing strokes without excessive bleeding

Biotech eXithera is a portfolio company of Israel’s Clal Biotechnology. It has developed an anti-coagulant which has successfully completed Phase 1 trials. The treatment delays coagulation rather than prevents it and its effects cease quickly when the treatment stops.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *